FDA Adverse Event Injury Summary report: N

V60 VENTILATOR

MDR report key: 6910209 · Received October 3, 2017

Report

Report Number
2031642-2017-03151
Event Type
Injury
Date Received
October 3, 2017
Date of Event
August 10, 2017
Report Date
September 22, 2017
Manufacturer
RESPIRONICS CALIFORNIA, INC
Product Code
MNT
PMA / PMN Number
K082660
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
CH
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

THE DETERMINATION COULD NOT BE MADE THAT THE DEVICE FAILED TO MEET SPECIFICATIONS. THE DEVICE WAS BEING USED FOR TREATMENT WHEN THE REPORTED EVENT OCCURRED, AND THERE IS A RELATIONSHIP OF THE DEVICE TO THE ADVERSE EVENT. GASTRIC DISTENTION IS A KNOWN PATIENT ISSUE WITH POSITIVE PRESSURE VENTILATION.

Additional Manufacturer Narrative · 1

THE AUTHORIZED SERVICE PROVIDER, (B)(4), CONFIRMED THERE WERE NO FAILURES WITH THE VENTILATOR. IT WAS CONFIRMED THAT GASTRIC DILATION WAS A DESCRIBED SIDE EFFECT IN THE USER MANUAL. THE CLINICAL STAFF AT THE HOSPITAL WERE GIVEN FURTHER TRAINING ON THIS.

Description of Event or Problem · 1

A PHYSICIAN REPORTED THAT A PATIENT HAD GASTRIC DISTENTION. THE PATIENT WAS ADMITTED FOR ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, HEART DISEASE, TYPE 2 RESPIRATORY FAILURE, RESPIRATORY ACIDOSIS, METABOLIC ALKALOSIS AND HYPERTENSION. THE PATIENT WAS ON THE VENTILATOR FOR APPROXIMATELY ONE WEEK, AND ON (B)(6) 2017, THE PATIENT HAD FLATULENCE, COULD NOT LIE SUPINE AND HAD CHEST TIGHTNESS. THE VENTILATOR WAS REMOVED AND THE PATIENT WAS TREATED WITH TONGLI SHENLING GRAUNULES 10G FOR SPLEEN AND STOMACH THREE TIMES A DAY) AND DOMPERIODONE MALEATE TABS 12.7MG. AFTER ONE WEEK OF TREATMENT THE PATIENT HAS NO FURTHER SYMPTOMS AND THE NASO-GASTRIC TUBE WAS NOT REQUIRED ANY LONGER.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
690051 V60 VENTILATOR VENTILATOR, CONTINUOUS, MINIMAL VENTILATORY SUPPORT,FACILITY USE MNT RESPIRONICS CALIFORNIA, INC V60

Patients

Seq Age Sex Outcome Treatment
1 67 YR Required Intervention